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Carnitine/organic cation transporter 2 (OCTN2) recognizes various cationic compounds 
as substrates in vitro, but information on its pharmacokinetic role in vivo is quite limited. Here we 
demonstrate altered tissue distribution of the OCTN2 substrate pyrilamine in juvenile visceral 
steatosis (jvs) mice, which have a hereditary defect of the octn2 gene. At 30 min after intravenous 
injection of pyrilamine, the tissue-to-plasma concentration ratio (Kp) in heart and pancreas was 
higher, whereas the Kp in kidney and testis was lower in jvs mice compared with wild-type mice. 
Pyrilamine transport studies in isolated heart slices confirmed higher accumulation, together with 
lower efflux, of pyrilamine in heart of jvs mice. The higher accumulation in heart slices of jvs 
mice was abolished by lowering the temperature, by increasing the substrate concentration, and in 
the presence of other H1 antagonists or another OCTN2 substrate, carnitine, suggesting that 
OCTN2 extrudes pyrilamine from heart tissue. On the other hand, the lower distribution to the 
kidney of jvs mice was probably due to down-regulation of a basolateral transporter coupled with 
OCTN2, because, in jvs mice, (i) Kp in kidney of pyrilamine assessed immediately after 
intravenous injection (~ 1 min) was also lower, (ii) urinary excretion of pyrilamine was lower, 
and (iii) uptake of pyrilamine in kidney slices was lower. The renal uptake of pyrilamine was 
saturable (Km ~236 µM) and was strongly inhibited by cyproheptadine, astemizole, ebastine and 
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terfenadine. The present study thus indicates that genetic deficiency of octn2 alters pyrilamine 
disposition tissue-dependently. 
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INTRODUCTION 
Carnitine/organic cation transporter 2 (OCTN2/SLC22A5) was first isolated as a novel 
transporter with high homology to OCTN1/SLC22A4 [1,2]. The endogenous substrate of OCTN2 
is a vitamin-like compound, carnitine, and deficiency of the OCTN2 gene leads to systematic 
carnitine deficiency (SCD) [3]. Carnitine is water-soluble, not membrane-permeable, and is 
required for ß-oxidation of fatty acids. In mammals, carnitine is supplied both by biosynthesis 
and from food intake.  
Juvenile visceral steatosis (jvs) mouse, which has a mutation in the octn2 gene 
(Leu352Arg), was found to exhibit SCD-like symptoms, such as cardiac hypertrophy, lipid 
accumulation in the liver and hyperammonemia [3-6]. Several pharmacokinetic studies using jvs 
mice have revealed that OCTN2 governs carnitine disposition in vivo: ingested carnitine is 
absorbed in the small intestine via OCTN2, moved to circulating blood, and taken up by the liver 
and other organs via OCTN2 [7-9]. Because of its limited plasma protein binding, carnitine is 
easily filtered in the glomerulus, but is efficiently reabsorbed in the kidney via OCTN2 [7]. The 
putative role of OCTN2 in carnitine homeostasis is consistent with the localization of OCTN2 on 
apical membranes of epithelial cells in the small intestine and kidney [9,10]. 
OCTN2 has also been reported to be involved in renal tubular secretion of 
tetraethylammonium (TEA), another OCTN2 substrate [11]. In addition to carnitine and TEA, 
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OCTN2 also transports various cationic compounds including pyrilamine, quinidine and 
verapamil [12-14]. However, identification of OCTN2 substrates has been performed using 
OCTN2-transfected cell line systems in vitro, and the pharmacokinetic role of OCTN2 in vivo has 
still not been fully elucidated. Recently, Grigat et al. presented in vitro evidence that OCTN2 
efficiently transports mildronate, though they considered that it is not a general drug transporter 
[15]. On the other hand, we have recently found that OCTN2 plays a major role in renal secretion 
of a β-lactam antibiotic, cephaloridine, using jvs mice [16].  
Among OCTN2 substrates, pyrilamine is a member of the first-generation H1 
antagonists, some of which, such as diphenhydramine and hydroxyzine, are widely used to treat 
allergic rhinitis and urticaria, despite their sedative side effect. The sedation is caused by their 
efficient distribution to the brain. In contrast to the first-generation compounds, 
second-generation H1 antihistamines cause less somnolence. In connection with this, transport 
mechanisms of antihistamines to the brain have been widely studied. One of the major 
transporters involved in the brain distribution of H1 antihistamines is P-glycoprotein (P-gp), the 
function of which as a drug efflux pump at the blood brain barrier (BBB) was originally clarified 
by Tsuji et al. using bovine primary cultured brain capillary endothelial cells [17], and 
subsequently confirmed in mdr1a gene knockout mice [18]. The permeability at the BBB of the 
nonsedative H1-antagonist ebastine and its metabolite carebastine was restricted by P-gp [19]. 
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Chen et al. have also shown that P-gp reduces the brain’s exposure to nonsedating 
second-generation, but not sedating first-generation, H1 antihistamines [20]. 
Other side effects provoked by certain H1 antagonists include cardiovascular toxicity. In 
particular, astemizole and terfenadine block rapid delayed rectifier K+ current, leading to serious 
adverse events, such as QT prolongation [21, 22]. Occurrence of this side effect depends on the 
affinity of drug for the K+ channel and on the drug concentration in cardiomyocytes. Therefore, it 
is necessary not only to clarify the interaction of drugs with the K+ channel, but also to elucidate 
the membrane permeation mechanism of these drugs in the heart, since the latter may influence 
the unbound concentration of the drugs inside cardiomyocytes. However, only limited 
information is available on transporter functions in cardiomyocytes. Recently, Iwata et al. have 
proposed that OCTN2 is localized on the sarcolemma of cardiomyocytes and on the membrane in 
the intercalated disc, and suggested that it is involved in the influx of carnitine into the heart [23]. 
In the present study, we aimed to examine the possible involvement of OCTN2 in the distribution 
of pyrilamine to the heart and other organs, using jvs mice as a tool to clarify the role of OCTN2 
in vivo. 
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MATERIALS AND METHODS 
Materials and animals 
 Pyrilamine was purchased from Sigma-Aldrich Japan K.K. (Tokyo, Japan). All other 
reagents were commercial products of reagent grade. Jvs mice, originally found among mice of 
the C3H.OH strain [24], and control (wild-type) C3H/HeJ mice (Japan SLC, Hamamatsu, Japan) 
were used. By mating heterozygous male and female mice, we obtained homozygous mutants 
(jvs/jvs) and wild-type mice. All the animal experiments were performed according to the 
Guidelines for the Care and Use of Laboratory Animals in Takara-machi Campus of Kanazawa 
University. 
 
Pharmacokinetic studies of pyrilamine in vivo 
Eight-week-old male mice were used after overnight starvation to study the disposition 
of pyrilamine. Mice were anesthetized with pentobarbital and injected with 3.75 mg/kg of 
pyrilamine via the right jugular vein as a bolus. Serial blood samples (20 µL) were collected at 
designated time intervals from the right jugular vein of each mouse using heparinized capillary 
tubes. Urine samples were collected at designated times by washing the bladder with saline 
through polyethylene tubing (SP31, Natsume, Tokyo, Japan). For determination of 
tissue-to-plasma concentration ratio (Kp), the mice were decapitated at 1 or 30 min after the 
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intravenous injection. Tissues were quickly excised, rinsed well with ice-cold saline, blotted to 
dryness, weighed and stored at -30°C until use. 
 
Uptake studies of pyrilamine in isolated heart and kidney slices 
Mice were sacrificed by decapitation under diethyl ether anesthesia. The heart and 
kidney were immediately excised and rinsed with about 50 mL of ice-cold saline. Atrium and 
connective tissues were carefully removed, and the heart was sectioned at 350 µm with a 
microslicer (DTK-2000, Dosaka EM Co. Ltd., Kyoto, Japan). The kidney was sectioned by the 
same method. The slices were then soaked in ice-cold Krebs-Ringer bicarbonate buffer (KRB 
buffer) containing 115 mM NaCl, 4.7 mM KCl, 1.1 mM MgCl2, 2.0 mM KH2PO4, 25 mM 
NaHCO3, 2.5 mM CaCl2 and 11 mM D-glucose. After 5 min pre-incubation, the heart and kidney 
slices were moved to KRB buffer containing 2 µM pyrilamine prewarmed at 37°C, with bubbling 
of 95% O2/5% CO2. This pyrilamine concentration (2 µM) was set to be as lower as possible to 
avoid any saturation in transport systems, but also to be higher enough for the determination of 
pyrilamine in both tissue slices and medium using HPLC. At designated times, slices were picked 
up from the incubation buffer and rinsed with about 50 mL of ice-cold saline. They were blotted 
dry, weighed and stored at -30°C until use.  
In the inhibition experiments, inhibitors were also included in the KRB buffer. In the 
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efflux experiments, the heart slices were first incubated in KRB buffer containing 2 µM 
pyrilamine for 60 min, washed with ice-cold KRB buffer and then moved to KRB buffer 
prewarmed at 37°C. At designated times, the slices were removed, washed with ice-cold KRB 
buffer, blotted dry, weighed and stored at -30°C until the HPLC determination. Efflux transport 
activity was evaluated by measuring the pyrilamine content remained in the slices. 
All the uptake values were expressed as slice-to-medium concentration (S/M) ratio per 
unit tissue weight (µL/mg tissue), obtained by dividing the amount of pyrilamine in the slices by 
the initial concentration in the medium and the weight of the slices. 
 
Measurement of blood-to-plasma concentration ratio and plasma protein binding 
Blood was taken from mice under pentobarbital anesthesia into heparinized tubes. A 
500 µL aliquot of blood was pre-incubated for 3 min at 37°C, and then spiked with 10 µL of drug 
solution. The mixture was incubated at 37°C for 30 min, and an aliquot was taken for 
determination of blood concentration (Cb). The plasma was separated by centrifugation of the 
residual mixture at 2,500 g at 20°C for 10 min. An aliquot of plasma was then taken for the 
determination of total plasma concentration (Cp). The remaining plasma was placed in an 
ultrafiltration apparatus (Centrifree, Amicon Inc., Beverly, MA) with a molecular mass cut-off of 
13 kD and centrifuged at 3,000 rpm (TOMY RL-100, Tokyo, Japan) for 10 min. After 
centrifugation, the concentration in the filtrate was determined as unbound concentration (Cu). 
The blood-to-plasma concentration ratio (Rb) was calculated by dividing Cb by Cp. The free 
fraction of pyrilamine in plasma (fp) was calculated by dividing Cu by Cp. All the binding was 
normalized with respect to the filter blank. 
Determination of pyrilamine 
The homogenized tissue samples, blood, plasma and urine were deproteinized with 
methanol and centrifuged at 10,000 g for 15 min. The supernatant was subjected to HPLC. The 
HPLC analysis for pyrilamine was performed using COSMOSIL 5C18-MS-Ⅱ(150 x 4.6 mm) 
(Nacalai Tesque, Kyoto, Japan). The mobile phase consisted of methanol/10 mM formate buffer 
(pH 3.75) (33/67). The UV detector was operated at a wavelength of 244 nm. Chlorpheniramine 
was used as an internal standard. 
 
Data analysis 
Kinetic parameters for uptake by tissue slices were obtained using nonlinear 
least-squares regression analysis [25] based on the following equation: 
v = V max× s
Km+ s +Kns× s  
where v, s, Vmax, Km, and Kns represent the initial uptake velocity, substrate concentration, 
maximum uptake velocity, Michaelis constant and non-saturable uptake clearance, respectively. 
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The selection of the equation was based on Akaike’s Information Criterion.  
 
Statistical analysis 
Statistical analyses were performed by means of Student’s t-test or ANOVA with 
Tukey’s post hoc comparison test for single and multiple comparisons, respectively. Differences 




Plasma concentration, urinary excretion and tissue distribution of pyrilamine in wild-type 
and jvs mice 
After intravenous injection of pyrilamine, little difference was observed in plasma 
concentration profile between wild-type and jvs mice (Fig. 1a). Urinary excretion of pyrilamine 
in jvs mice was lower than that in wild-type mice (Fig. 1b). The fraction of the dose excreted into 
urine during 240 min after the injection was at most 2-6% (Fig. 1b). It has been reported that 
30-40% of the dose was recovered in urine following i.v. administration of [14C]pyrilamine 
within 24 hr, predominantly as a glucuronide metabolite, whereas urinary excretion of unchanged 
pyrilamine was less than 10% in rats [26]. The present study also indicated that renal excretion 
would be a minor elimination pathway for pyrilamine in mice (Fig. 1b). Due to quantification 
limit for pyrilamine by HPLC system in the present study, time course of plasma pyrilamine 
concentration could be chased until 120 min (Fig. 1a), and this was the reason for inconsistent 
time periods between plasma concentration and urinary excretion profiles (Fig. 1a, 1b). 
On the other hand, at 30 min after intravenous injection, the Kp of pyrilamine in heart 
and pancreas was 1.8 and 1.5 times larger, respectively, in jvs mice compared with wild-type 
mice (Table 1). The Kp in the small intestine of jvs mice was also 3.8-fold higher than that in 
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wild-type mice, although this difference was not statistically significant. The Kp values in kidney 
and testis of jvs mice, on the other hand, were about 15 and 65% of those in wild-type mice 
(Table 1). Thus, the change in distribution of pyrilamine in jvs mice was tissue-dependent. The 
Kp values were also determined at 1 min after intravenous injection, and that in kidney of jvs 
mice was again significantly lower than that in wild-type mice (Table 1). The Kp at 1 min after 
injection in heart of jvs mice tended to be higher than that in wild-type mice, although this 
difference was not significant (Table 1). The values for plasma unbound fraction (fp) of 
pyrilamine in wild-type and jvs mice were 0.685 ± 0.093 and 0.513 ± 0.093, whereas the values 
for blood-to-plasma concentration ratio (Rb) were 1.66 ± 0.11 and 1.74 ± 0.23, respectively, 
showing no significant difference between the two strains. 
 
Influx and efflux of pyrilamine in isolated heart slices 
The difference in heart distribution between wild-type and jvs mice may be explained 
by differences in tissue binding, influx and/or efflux processes. To investigate the transport 
mechanism in detail, uptake studies using heart slices were performed. Accumulation of 
pyrilamine in heart slices at 10 min was similar in wild-type and jvs mice, whereas after 60 min, 
that in jvs mice was higher than that in wild-type mice (Fig. 2a). In addition, pyrilamine content 
remaining in the heart slices was determined after 60 min preincubation with pyrilamine in order 
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to directly examine the efflux process from the heart. The amount of pyrilamine that remained in 
the heart slices of jvs mice was higher than that in heart slices of wild-type mice (Fig. 2b), 
suggesting that there is a difference in the efflux process between wild-type and jvs mice. 
The larger accumulation (Fig. 2a) and lower efflux (Fig. 2b) in the heart slices of jvs 
mice may be explained by a decrease in efflux of pyrilamine from the heart of jvs mice. To 
investigate whether or not the difference between wild-type and jvs mice was due to a 
carrier-mediated system, we then examined the influence of an excess concentration (20 mM) of 
pyrilamine, carnitine, or H1 antagonists and of a lower temperature (4°C). For this purpose, the 
accumulation of pyrilamine was determined after 120 min incubation, when the difference 
between wild-type and jvs mice was clear (Fig. 2a). Disappearance of the difference between the 
two strains in the presence of an inhibitor would suggest inhibition of the efflux process of 
pyrilamine, whereas a decrease in the absolute value of pyrilamine accumulation in the presence 
of the inhibitor would indicate inhibition of the influx process and/or tissue binding. The 
difference in the accumulation of pyrilamine was diminished at 4°C. (Fig. 3a). At 20 mM 
pyrilamine, the difference in accumulation between wild-type and jvs mice was reduced 
compared with the control (2 µM pyrilamine), but there was still a significant difference (Fig. 3a). 
The absolute value of the pyrilamine accumulation was also reduced in both strains (Fig. 3a). The 
significant difference in pyrilamine accumulation between wild-type and jvs mice also 
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disappeared in the presence of 20 mM carnitine (Fig. 3a). The concentration of pyrilamine and 
carnitine (20 mM) was set as higher as possible so that saturation and/or inhibition can be 
observed in the pyrilamine accumulation (Fig. 3a). The osmotic control was not used in 
combination with this study, and it would be possible that the osmotic pressure may affect the 
membrane transporters. Next, we examined the influence of various antihistamines on the 
pyrilamine accumulation for 120 min in heart slices. Due to limited solubility, the concentration 
of ebastine, astemizol and terfenadine was set to be 50 µM, whereas the concentration of highly 
soluble diphenhydramine was set at 5 mM (Fig. 3b). Diphenhydramine, promethazine, ebastine 
and carebastine also diminished the difference in pyrilamine accumulation between wild-type and 
jvs mice (Fig. 3b). Cyproheptadine, diphenhydramine and promethazine also decreased the 
absolute value of pyrilamine accumulation in both strains, whereas promethazine did not (Fig. 
3b). The pyrilamine accumulation by heart slices of jvs mice was significantly different from that 
in wild-type mice even in the presence of cyproheptadine, astemizol, terfenadine and 
fexofenadine (Fig. 3b). 
 
Renal handling of pyrilamine in wild-type and jvs mice 
To investigate renal transport of pyrilamine, uptake studies were performed in isolated 
kidney slices. Uptake of pyrilamine in kidney slices of wild-type mice gradually increased, 
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whereas the increase in jvs mice was much smaller (Fig. 4a). The initial uptake of pyrilamine 
assessed in kidney slices of wild-type mice for 10 min was saturable (Fig. 4b), and kinetic 
analysis revealed saturable and unsaturable components with Km of 236 ± 165 µM, Vmax of 
1.62 ± 0.96 nmol/mg tissue/10 min and Kns of 1.91 ± 0.40 µL/mg tissue/10 min. 
Initial uptake of pyrilamine in kidney slices of wild-type mice was reduced to 15 and 
34% of the control in the presence of 20 mM pyrilamine and at 4°C, respectively (Fig. 5a). The 
uptake after preincubation with ATP depletors (10 mM NaN3 plus 10 mM NaF) for 15 min was 
64% of the control (Fig. 5a). Thus, the uptake is temperature- and energy-dependent. On the other 
hand, 1 mM carnitine had only a minimal effect on pyrilamine uptake in kidney slices (Fig. 5a). 
To further characterize the influx process of pyrilamine, the effect of antihistamines was also 
examined in kidney slices. The pyrilamine uptake was significantly inhibited by 
diphenhydramine, cyptoheptadine, astemizole, ebastine, terfenadine and carebastine, but less so 
by fexofenadine (Fig. 5b). The effect of typical substrates of renal transporters on pyrilamine 
uptake was also examined, but tetraethylammonium (TEA), para-aminohippurate (PAH), 
benzylpenicillin (PCG) and digoxin minimally affected the pyrilamine uptake (Fig. 5c). 
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DISCUSSION 
Although many in vitro studies have indicated that OCTN2 is a drug transporter with 
broad substrate specificity, in vivo evidence of its role is quite limited. In the present study, we 
aimed to clarify the role of OCNT2 in the disposition of an H1 antagonist, pyrilamine, in vivo. 
When the tissue distribution of pyrilamine was compared between wild-type and jvs mice, the Kp 
values in heart and pancreas were found to be increased, whereas those in kidney and testis were 
decreased, as a result of the deficiency of octn2 gene (Table 1), although systemic exposure to 
pyrilamine was similar in the two strains (Fig. 1a). The jvs mice have a hereditary mutation in the 
octn2 gene, resulting in functional deficiency of the octn2 gene product [3-6]. Therefore, the 
present findings indicate that the tissue distribution of pyrilamine is influenced by octn2 gene 
deficiency. We have previously demonstrated that the Kp values of TEA in brain, lung, liver and 
spleen of jvs mice were lower than those in wild-type mice [11]. Similarly, the Kp values of 
carnitine was also lower in several organs of jvs mice [7]. Since TEA and carnitine are substrates 
of OCTN2 [11,12], and OCTN2 is ubiquitously expressed in many organs [27], OCTN2 may 
function as an influx transporter in these organs. Pyrilamine is also a substrate of OCTN2 [11,12], 
but the change in Kp values of pyrilamine associated with octn2 gene deficiency was different 
from those for TEA and carnitine, and was tissue-dependent. For example, the Kp of carnitine in 
heart and pancreas of jvs mice was lower than that in wild-type mice [7], whereas the Kp of 
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pyrilamine in jvs mice was higher (Table 1). Therefore, the molecular mechanism(s) of the octn2 
gene-associated change in tissue distribution of pyrilamine should be carefully considered. 
The Kp value is generally affected by several kinetic parameters, including unbound 
fraction in plasma and tissues, and permeability clearance for influx and efflux processes. The 
unbound fraction in plasma of pyrilamine was similar in wild-type and jvs mice (see Results). 
Therefore, OCTN2 might be either directly or indirectly involved in tissue binding and/or 
membrane permeation. The Kp of pyrilamine in heart of jvs mice was significantly higher than 
that in wild-type mice 30 min after injection, but the difference was not so marked at 1 min after 
injection (Table 1). This result was confirmed in uptake studies with heart slices: the difference in 
pyrilamine accumulation in heart slices between wild-type and jvs mice was more marked at 60 
min and later after the start of incubation (Fig. 2a). In addition, after preloading pyrilamine into 
heart slices, efflux of pyrilamine from the heart slices was delayed in jvs mice, compared with 
wild-type mice (Fig. 2b). These kinetic data obtained both in vivo and in vitro may suggest that 
OCTN2 functions as an efflux transporter for pyrilamine in heart. This hypothesis is further 
supported by the recent observation that OCTN2 is localized at plasma membrane of cardiac 
muscle cells in mice [23] and vascular endothelium in human heart [28]. In addition, the greater 
accumulation of pyrilamine in heart slices of jvs mice, compared with wild-type mice, was 
decreased or diminished in the presence of 20 mM pyrilamine, carnitine or several H1 
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antihistamines (Fig. 3). The higher accumulation of pyrilamine in jvs mice was also diminished at 
4oC, at which active transport systems show minimal activity (Fig. 3a). These findings can also 
be explained if we consider the existence of an efflux transporter for pyrilamine which is 
saturable, sensitive to carnitine and several antihistamines, and temperature-dependent. However, 
the absolute values of pyrilamine accumulation were also decreased under various conditions 
(Fig. 3), and a possible effect on tissue binding and/or influx of pyrilamine cannot be excluded. In 
addition, carnitine failed to inhibit the pyrilamine accumulation in heart slices, whereas the 
difference of pyrilamine accumulation between wild-type and jvs mice was diminished in the 
presence of excessive carnitine (Fig. 3a). If we consider that carnitine is a good substrate for 
OCTN2, it would be possible that other unknown pyrilamine transporter than OCTN2 may play a 
role in the influx of pyrilamine. 
Despite the previous observations indicating OCTN2-mediated transport of therapeutic 
agents in vitro [12-14], the present finding is the first to suggest the role of OCTN2 in drug 
disposition to the heart in vivo. There are quite few studies dealing with the pharmacokinetic 
role(s) of transporters in the heart in vivo. Zwart et al. demonstrated that distribution of MPP to 
the heart was decreased in organic cation transporter (OCT) 3 gene knockout mice, proposing 
that OCT3 is functionally expressed in heart as an influx transporter [29]. Higher levels of 
distribution to the heart of vinblastine and [14C]grepafloxacin in gene knockout mice for 
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multidrug resistance protein 1 and multidrug resistance-associated protein (Mrp) 1, respectively, 
were also reported, suggesting that P-glycoprotein and Mrp1 function as efflux transporters in the 
heart [30,31]. In the present study, we also examined the effect of various H1 antihistamines on 
pyrilamine accumulation in heart slices (Fig. 3). Among H1 antagonists, diphenhydramine, 
promethadine, ebastine and carebastine diminished the difference in pyrilamine accumulation 
between wild-type and jvs mice (Fig. 3b), whereas astemizole and terfenadine, both of which are 
known to block rapid delayed rectifier K+ current, leading to QT prolongation in the heart [21,22], 
had minimal effects on pyrilamine accumulation (Fig. 3b). The efflux transporter would affect 
unbound drug concentration in the heart tissue, which is primarily important for K+ channel 
inhibition. Therefore, further toxicological studies focusing on the role of OCTN2 and other 
transporters in the disposition of H1 antihistamines in heart are needed. 
The mechanism of the difference in Kp value of the kidney between wild-type and jvs 
mice is likely to be more complicated. The lower Kp value in the kidney of jvs mice (Table 1) 
suggests that the reduction in urinary excretion in jvs mice (Fig. 1b) may be attributable to 
decreased uptake in renal epithelial cells. This hypothesis would be compatible with the present 
finding that a lower Kp value in jvs mice was observed within a short period (~1 min) after 
pyrilamine injection (Table 1), and that the uptake of pyrilamine in isolated kidney slices of jvs 
mice was also lower than that of wild-type mice (Fig. 4a). Thus, the uptake of pyrilamine, which 
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presumably occurs at the basolateral membrane, was reduced in jvs mice. On the other hand, 
immunohistochemical study has revealed that OCTN2 is localized on the brush-border membrane 
of renal proximal cells [10]. Therefore, certain transporter(s) directly or indirectly associated with 
OCTN2 may be involved in pyrilamine uptake at the basolateral membrane. Uptake studies with 
kidney slices have shown that the pyrilamine transporter on the basolateral membrane is not 
influenced by inhibitors of known basolateral membrane transporters, such as OCTs, organic 
anion transporters and organic anion transporting polypeptides (Fig. 5c). The uptake transporter 
has high affinity for pyrilamine, with Km of 236 µM (Fig. 4b), and is strongly inhibited by 
cyproheptadine, astemizole and ebastine (Fig. 5b), all of which mainly exist as cationic forms at 
physiological pH. These characteristics are similar to those of the pyrilamine uptake system 
previously observed in brain capillary endothelial cells [32-35]. 
OCTN2 is localized on apical membranes of renal proximal tubules and involved in 
renal tubular secretion of TEA [11]. Our recent study has also revealed that cephaloridine is 
secreted into urine by OCTN2 [16]. Consequently, it is possible that OCTN2 is also involved in 
pyrilamine secretion at apical membrane of renal epithelial cells. However, reduction in both 
urinary excretion of pyrilamine and Kp value for kidney (~1 min) in jvs mice (Fig. 1b, Table 1) 
indicates that renal secretion of pyrilamine at apical membrane is not rate limiting step. Thus, the 
involvement of OCTN2 in pyrilamine secretion at apical membrane could not be demonstrated in 
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the present study. 
Pyrilamine is highly distributed to the brain (Kp value of 12 ~ 14; Table 1). Although 
we could not demonstrate that OCTN2 is the pyrilamine transporter in the brain in the present 
study, the Kp value in the brain of jvs mice tended to be higher than that in wild-type mice (Table 
1), suggesting that OCTN2 may be involved in pyrilamine distribution to the brain. Recently, 
Okura et al. have reported that oxycodone, a weak cationic drug and an opioid agonist used for 
treatment of moderate to severe cancer pain, is transported into the brain partially via the 
pyrilamine transporter [34]. Because these transporters presumably localized at the blood-brain 
barrier would affect unbound drug concentration inside the brain, it is essential to identify the 
pyrilamine transporter in order to understand the mechanism of sedation by H1 antagonists and 
the efficacy of drugs targeting the central nervous system. 
 Regarding the tissue distribution of carnitine, significant difference of its Kp values 
between wild-type and jvs mice was observed in many tissues, and this was compatible to 
expression profile of OCTN2 in ubiquitous tissues [7, 27]. In the present study, however, the 
alteration of pyrilamine Kp values in jvs mice was observed only in heart, pancreas, kidney and 
testis. This may be because other transporter(s) than OCTN2 would be involved in the tissue 
distribution of pyrilamine. We have previously reported that pyrilamine is efficiently taken up 
into brain via saturable transport system [32, 33, 35]. This “pyrilamine transporter” is probably 
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different from OCTN2 because of to the difference in transport characteristics such as Na+- and 
pH dependency [34]. If the contribution of other transporter(s) to overall tissue distribution of 
pyrilamine is higher than that of OCTN2, the involvement of OCTN2 in tissue distribution of 
pyrilamine would not be observed, leading to discrepancy between the alteration of Kp values 
and expression of OCTN2. Therefore, OCTN2 would be one of the transporters involved in tissue 
distribution of pyrilamine. 
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CONCLUSION 
in vivo and in vitro pharmacokinetic studies revealed that OCTN2 is involved in 
pyrilamine distribution to at least heart and kidney. This is the first evidence that OCTN2 may act 
as an efflux transporter for therapeutic agents in the heart in vivo. Further studies are needed to 
clarify the role of OCTN2 in the heart to understand its toxicological relevance, and jvs mice may 
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LEGENDS TO FIGURES  
Figure 1 
Plasma concentration (A) and cumulative urinary excretion (B) of pyrilamine 
Pyrilamine was intravenously administered at a dose of 3.75 mg/kg to wild-type (open circles) 
and jvs (closed circles) mice. Data are expressed as mean ± S.E.M (n = 3-8). Where an error bar 
is not shown, it is smaller than the symbol. 
 
Figure 2 
Time-dependent uptake (A) and efflux (B) of pyrilamine in isolated heart slices 
(A) Uptake of pyrilamine in heart slices of wild-type (open circles) and jvs mice (closed circles) 
was measured during incubation with pyrilamine (2 µM) at 37oC. (B) Heart slices of wild-type 
(open circles) and jvs mice (closed circles) were pre-incubated with 2 µM pyrilamine for 60 min, 
washed with ice-cold buffer, and incubated at 37oC in the absence of pyrilamine for the indicated 
periods. Data represent amount of pyrilamine remaining in the slices, normalized by the amount 
just after the pre-incubation, and are expressed as mean ± S.E.M. (n = 3-4). Where an error bar is 




Effect of temperature, carnitine and antihistamines on accumulation of pyrilamine in 
isolated heart slices 
(A) Accumulation of pyrilamine (2 µM) in heart slices of wild-type (open bars) and jvs mice 
(closed bars) was measured at 37oC for 120 min, at which time, the accumulated amount was 
close to the steady-state value (see Fig. 2), in the presence of 20 mM pyrilamine or carnitine, or at 
4oC. (B) The accumulation of pyrilamine (2 µM) in heart slices of wild-type (open bars) and jvs 
mice (closed bars) was measured for 120 min at 37oC in the presence or absence of 
antihistamines at designated concentrations. Data are expressed as mean ± S.E.M. (n = 3-4). 
Where an error bar is not shown, it is smaller than the symbol. *p<0.05 
 
Figure 4 
Time course (A) and concentration dependence (B) of the uptake of pyrilamine in isolated 
kidney slices 
(A) The uptake of pyrilamine (2 µM) in kidney slices of wild-type (open circles) and jvs mice 
(closed circles) was measured at 37oC. (B) The uptake of pyrilamine at various concentrations in 
kidney slices of wild-type mice was measured for 10 min at 37oC. The pyrilamine concentrations 
were set to be 30, 50, 100, 300, 500, 750, 1000, 3000, 5000, 10000 and 20000 µM. Data are 
presented as an Eadie-Hofstee plot and expressed as mean ± S.E.M. (n = 3-4). Where an error bar 
 35
is not shown, it is smaller than the symbol. *p<0.05 
 
Figure 5 
Effect of temperature and carnitine (A), transporter substrates (B) and antihistamines (C) 
on pyrilamine uptake in isolated kidney slices 
Uptake of pyrilamine (2 µM) in kidney slices of wild-type mice was measured at 37oC for 10 min 
in the presence or absence of each compound at the designated concentration. In panel (A), the 
incubation was also performed at 4oC. Data are expressed as mean ± S.E.M. (n = 3-4). Where an 
error bar is not shown, it is smaller than the symbol. *p<0.05 
 Table 1 
Values of tissue-to-plasma concentration ratio (Kp) of pyrilamine in wild-type and jvs mice a
 
  Wild-type jvs 
 Kp (30 min) b
 Brain 11.8 ± 0.8 14.3 ± 1.1 
 Fat 7.11 ± 0.46 7.65 ± 0.87 
 Heart 6.01 ± 0.44 10.6 ± 1.1d
 Intestine 0.432 ± 0.154 1.68 ± 0.82 
 Kidney 88.2 ± 17.8 13.8 ± 3.2d
 Lung 24.7 ± 1.5 18.9 ± 2.1 
 Pancreas 26.7 ± 1.0 40.7 ± 6.9d
 Spleen 35.1 ± 2.8 32.4 ± 4.8 
 Testis 20.2 ± 1.1 13.1 ± 2.0d
 Kp (1 min) c
 Heart 34.1 ± 3.4 43.9 ± 5.5 
 Kidney 43.3 ± 4.6 24.4 ± 2.8d
a Data were expressed as mean ± S.E.M (n = 4-6) 
b The Kp values were measured at 30 min after intravenous administration of pyrilamine at a dose 
of 3.75 mg/kg. 
c The Kp values were measured at 1 min after intravenous administration of pyrilamine at a dose 
of 3.75 mg/kg.  
d Significantly different from wild-type mice. p<0.05 
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